Search Results - "TANHEHCO, Yvette C"

Development of curative therapies for sickle cell disease by Tanhehco, Yvette C, Nathu, Ghazala, Vasovic, Ljiljana V

“…Recent advances in managing Sickle Cell Disease (SCD) significantly improved patient survival and quality of life. Disease-modifying drug therapies such as…”
Get full text

Functional biomarkers for sickle cell disease by Tanhehco, Yvette C.

“…See article on page 1752–1761, in this issue…”
Get full text

Red Blood Cell Transfusion by Tanhehco, Yvette C.

“…Red blood cell (RBC) transfusions are necessary to increase a patient’s oxygen carrying capacity. The optimal transfusion trigger remains elusive, but a…”
Get full text

Guest Editors Bio by Tanhehco, Yvette C.

Get full text

Is a universal cure for sickle cell disease imminent? by Tanhehco, Yvette C.

Get full text

Effect of temporary storage of cryopreserved cellular therapy products at −80⁰ celsius on cell recovery and viability by Cohen, Tobias, Tanhehco, Yvette C.

“…Cellular therapy (CT) involving the transplantation of hematopoietic progenitor cells (HPC) is a treatment modality for both benign and malignant disorders…”
Get full text

Gene therapy for hemoglobinopathies by Tanhehco, Yvette C.

“…Beta hemoglobinopathies such as sickle cell disease (SCD) and β-thalassemia (BT) are the most common monogenic diseases worldwide. Both diseases are associated…”
Get full text

Hematopoietic stem cell transplantation and cellular therapy in sickle cell disease: where are we now? by Tanhehco, Yvette C, Bhatia, Monica

“…PURPOSE OF REVIEWSickle cell disease (SCD) is a common monogenic disorder that is characterized by an A to T substitution in the β-globin gene that leads to…”
Get full text

Red blood cell reduction of a sickle cell disease stem cell product by Tanhehco, Yvette C., Delgado, Ana Catalina

Get full text

RhD-positive red blood cell allocation practice to RhD-negative patients before and during the COVID-19 pandemic by Tanhehco, Yvette C, Fung, Mark, Hermelin, Daniela, Becker, Jennifer, Lu, Wen

“…The red blood cell (RBC) D antigen is highly immunogenic, and anti-D alloimmunization can cause hemolytic transfusion reactions and hemolytic disease of the…”
Get full text

How the COVID‐19 pandemic changed cellular therapy at Columbia University Irving Medical Center/NewYork‐Presbyterian Hospital by Tanhehco, Yvette C., Schwartz, Joseph

“…New York is at the epicenter of the coronavirus disease 2019 (COVID‐19) pandemic caused by the SARS‐CoV‐2 virus. Columbia University Irving Medical…”
Get full text

Low-density lipoprotein apheresis reduces platelet factor 4 on the surface of platelets: a possible protective mechanism against heparin-induced thrombocytopenia and thrombosis by Tanhehco, Yvette C., Rux, Ann H., Sachais, Bruce S.

“…BACKGROUND: Heparin‐induced thrombocytopenia and thrombosis (HITT) is characterized by thrombocytopenia due to the formation of antibodies against heparin :…”
Get full text

Under the hood: The molecular biology driving gene therapy for the treatment of sickle cell disease by Waldron, Evan, Tanhehco, Yvette C.

“…Gene therapy will soon become the dominant modality for treating of sickle cell disease (SCD). Currently, three technologies are the most promising: expression…”
Get full text

Characteristics of blood banking/transfusion medicine fellows in the United States, 2013–2021: Lessons learned from the Transfusion Medicine In‐Service Examination (TMISE) practice survey by Karafin, Matthew S., Tanhehco, Yvette C., Kreuter, Justin D.

Get full text

Virus-Associated Tumor Imaging by Induction of Viral Gene Expression by FU, De-Xue, TANHEHCO, Yvette C, JIANMENG CHEN, FOSS, Catherine A, FOX, James J, LEMAS, Victor, CHONG, Ja-Mun, AMBINDER, Richard F, POMPER, Martin G

“…Purpose: EBV and other herpesviruses are associated with a variety of malignancies. The EBV thymidine kinase (TK) is either not expressed or is expressed at…”
Get full text

Gender differences in scholarly productivity of early‐career transfusion medicine physicians by Ipe, Tina S., Tanhehco, Yvette C., Booth, Garrett S., Adkins, Brian D.

“…Background and Objectives Promotion in academic medicine requires evidence of the creation and dissemination of scholarly output, primarily through…”
Get full text

How we manage clinical trials in the cellular therapy laboratory by Tanhehco, Yvette C., Schwartz, Joseph

Get full text

How do I manage a blood product shortage? by Gammon, Richard, Becker, Joanne, Cameron, Tracy, Eichbaum, Quentin, Jindal, Aikaj, Lamba, Divjot Singh, Nalezinski, Shaughn, Rios, Jorge, Shaikh, Salima, Shepherd, Janine, Tanhehco, Yvette C.

“…Background The demand for blood products sometimes exceeds the available inventory. Blood product inventories are dependent upon the availability of donors,…”
Get full text

Novel therapeutic approaches for thrombotic thrombocytopenic purpura by Tanhehco, Yvette C, Arepally, Gowthami, Metjian, Ara

“…PURPOSE OF REVIEWAcquired thrombotic thrombocytopenic purpura is an immune-mediated thrombotic microangiopathy caused by antibodies to ADAMTS13 (A Disintegrin…”
Get full text

Academic Productivity of Early Career Transfusion Medicine Specialists: A Workforce Study by Tanhehco, Yvette C., Ipe, Tina S., Booth, Garrett S., Adkins, Brian D.

“…•All Blood Banking and Transfusion Medicine Specialists from a 3-year cohort are currently employed.•Blood Banking and Transfusion Medicine Specialists have…”
Get full text